Proteinase inhibitors are of high pharmaceutical interest and are drug candidates for a variety of indications. Specific kallikrein inhibitors are important for their antitumor activity and their potential application to the treatment of skin diseases. In this study we describe the synthesis of domain 6 of the kallikrein inhibitor Lympho-Epithilial Kazal-Type Inhibitor (LEKTI) by the fragment condensation method and site-directed cystine bridge formation. To obtain the linear LEKTI precursor, the condensation was best performed in solution, coupling the protected fragment 1-22 to 23-68. This method yielded LEKTI domain 6 of high purity and equipotent to the recombinantly produced peptide.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bip.21376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting kallikrein proteases for dandruff therapy.
Acta Dermatovenerol Alp Pannonica Adriat
December 2024
Department of Biochemistry, Faculty of Medicine and Health Sciences, Christian University of Krida Wacana, Jakarta, Indonesia.
Kallikrein proteases (KPs) are vital enzymes involved in the formation of dermatosomes and are regulated by the body's internal inhibitors. Maintaining a balance between KPs and their inhibitors is essential for promoting a healthy scalp. The scalp specifically contains two KPs: human kallikrein (hK) 5 and hK7, which are encoded by their respective genes.
View Article and Find Full Text PDFRapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
LEKTI domain 6 displays anti-inflammatory action in vitro and in a murine atopic dermatitis model.
J Dermatol Sci
July 2024
Institute of Pharmacology and Toxicology, Department of Veterinary Medicine, Freie Universität Berlin, Germany. Electronic address:
Background: Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a serine protease inhibitor consisting of multiple domains. A loss of function mutation is described in Netherton patients that show severe symptoms of atopic lesions and itch.
Objectives: LEKTI domain 6 (LD6) has shown strong serine protease-inhibitory action in in vitro assays and thus it was tested in vitro and in vivo for potential anti-inflammatory action in models of atopic skin disease.
Development of a back-titration assay to quantitate functional lympho-epithelial Kazal-type inhibitors (LEKTI) in skin samples.
Anal Biochem
July 2024
Azitra Inc, 21 Business Park Drive, Branford, CT, 06405, USA.
The lympho-epithelial Kazal-type inhibitors (LEKTI) are key to control skin turnover, and their absence causes Netherton syndrome. For clinical sample testing of LEKTI-based therapies, a robust analytical method to measure LEKTI-like activity in skin is required. This work reports on the development of a back-titration method to determine incremental LEKTI-like activity in skin samples.
View Article and Find Full Text PDFSPINK5 inhibits esophageal squamous cell carcinoma metastasis via immune activity.
J Gene Med
March 2024
Department of Oncology, Jiangyin People's Hospital, Jiangyin Clinical College of Xuzhou Medical University, Jiangyin Hospital Affiliated to Nantong University, Jiangyin, Jiangsu, China.
Background: Esophageal squamous cell carcinoma (ESCC) is a predominant subtype of esophageal cancer with relatively high mortality worldwide. Serine peptidase inhibitor Kazal-type 5 (SPINK5) is reported to be downregulated in ESCC. However, its explicit role in ESCC remains further investigation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!